Cancer and thrombosis
van Es, N.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
CANCER AND THROMBOSIS

improvements in strategies for prediction, diagnosis, and treatment

Nick van Es
CANCER AND THROMBOSIS:
IMPROVEMENTS IN STRATEGIES FOR
PREDICTION, DIAGNOSIS, AND TREATMENT

Nick van Es
CANCER AND THROMBOSIS: IMPROVEMENTS IN STRATEGIES FOR PREDICTION, DIAGNOSIS, AND TREATMENT

ACADEMISCH PROEFSCHRIFT

ter verkrijging van de graad van doctor
aan de Universiteit van Amsterdam
op gezag van de Rector Magnificus
    prof. dr. ir. K.I.J. Maex
ten overstaan van een door het College voor Promoties ingestelde commissie,
in het openbaar te verdedigen in de Agnietenkapel
    op vrijdag 17 november 2017, te 14.00 uur

door

Nick van Es

geboren te Naarden
PROMOTIECOMMISSIE

Promotores
prof. dr. S. Middeldorp AMC-UvA
prof. dr. P.M.M. Bossuyt AMC-UvA

Copromotores
prof. dr. H.R. Büller AMC-UvA
dr. M. Di Nisio Università degli studi Gabriele d'Annunzio di Chieti

Overige leden:
prof. dr. D.P.M. Brandjes AMC-UvA
prof. dr. S.C. Cannegieter LUMC
prof. dr. F.W.G. Leebeek Erasmus MC Rotterdam
dr. J.M.M.B. Otten Slotervaartziekenhuis, Amsterdam
prof. dr. R.J.G. Peters AMC-UvA
prof. dr. H.C.P.M. van Weert AMC-UvA

Faculteit der geneeskunde
PROMOTIECOMMISSIE

Promotores
prof. dr. S. Middeldorp    AMC‐UvA
prof. dr. P.M.M. Bossuyt   AMC‐UvA

Copromotores
prof. dr. H.R. Büller     AMC‐UvA
dr. M. Di Nisio          Università degli studi Gabriele d'Annunzio di Chieti

Overige leden:
prof. dr. D.P.M. Brandjes   AMC‐UvA
prof. dr. S.C. Cannegieter   LUMC
prof. dr. F.W.G. Leebeek    Erasmus MC Rotterdam
dr. J.M.M.B. Otten         Slotervaartziekenhuis, Amsterdam
prof. dr. R.J.G. Peters    AMC‐UvA
prof. dr. H.C.P.M. van Weert   AMC ‐UvA

Faculteit der geneeskunde
CONTENTS

CHAPTER 1  General introduction and outline  10
CHAPTER 2  Deep vein thrombosis and pulmonary embolism  18

PART I  Improvements in strategies for prediction

CHAPTER 3  Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study  52
CHAPTER 4  The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer: a retrospective cohort study  74
CHAPTER 5  The Khorana score for the prediction of venous thromboembolism in patients with solid cancer: an individual patient data meta-analysis  90
CHAPTER 6  Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study  108
CHAPTER 7  Risk prediction for venous thromboembolism in patients with solid cancer: derivation and validation of a clinical prediction model  126

PART II  Improvements in strategies for diagnosis

CHAPTER 8  Wells rule and D-dimer testing to rule out pulmonary embolism: a systematic review and individual patient data meta-analysis  146
CHAPTER 9  The original and simplified Wells rules and age-adjusted D-dimer testing to rule out pulmonary embolism: an individual patient data meta-analysis  168
CHAPTER 10 Screening for occult cancer screening in patients with unprovoked venous thromboembolism: a systematic review and individual patient data meta-analysis  184
### Part III  Improvements in strategies for treatment

<table>
<thead>
<tr>
<th>CHAPTER 11</th>
<th>Direct oral anticoagulants compared with vitamin K antagonists for acute symptomatic venous thromboembolism: clinical evidence from phase 3 trials</th>
<th>210</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHAPTER 12</td>
<td>Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial</td>
<td>230</td>
</tr>
<tr>
<td>CHAPTER 13</td>
<td>Edoxaban for treatment of venous thromboembolism in patients with cancer: rationale and design of the Hokusai VTE-cancer study</td>
<td>250</td>
</tr>
<tr>
<td>CHAPTER 14</td>
<td>Summary and perspectives</td>
<td>262</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>APPENDICES</th>
<th>Nederlandse samenvatting</th>
<th>276</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>List of peer-reviewed publications</td>
<td>280</td>
</tr>
<tr>
<td></td>
<td>Authors and affiliations</td>
<td>283</td>
</tr>
<tr>
<td></td>
<td>Portfolio</td>
<td>290</td>
</tr>
<tr>
<td></td>
<td>Dankwoord</td>
<td>294</td>
</tr>
<tr>
<td></td>
<td>About the author</td>
<td>297</td>
</tr>
</tbody>
</table>